CCL2 and hepatocellular carcinoma: Teng et al. found that CCL2 is strongly upregulated in patients with HCC, and that gene silencing and administration of a neutralizing antibody to CCL2 or a CCR2 antagonist reduced recruitment of circulating monocytes, then decreased TAMs number, and downregulated M2 secretion function as TAMs.